Status:
UNKNOWN
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
Lead Sponsor:
Methodist Health System
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy pe...
Detailed Description
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy pe...
Eligibility Criteria
Inclusion
- 1\. \>18 years of age
- 2\. Diagnosed with PSMA-positive metastatic castration-resistant prostate cancer and - has consented to undergo PSMA nuclear therapy per the treating physician. Specifically:
- Metastatic or Locally Advanced AND Inoperable
- Clear disease progression on PSMA-PET/CT
- PSMA-PET/CT scan positive disease within 6 weeks
- Labs:
- Hemoglobin: \>8 g/dL
- White blood cell count: \>2K cells/µL
- Platelet (Thrombocyte) count: \>75 x 109/L
- No prior therapy with Radium-223 Dichloride
Exclusion
- Patients who do not meet the Inclusion Criteria laid out in section 4.2 will be excluded from the study.
Key Trial Info
Start Date :
August 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 2 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05995236
Start Date
August 2 2023
End Date
August 2 2024
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203